Tracon pharmaceuticals, inc. (TCON)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities
Net loss

-22,674

-34,959

-19,103

-27,008

-

-

-

Net loss

-

-

-

-

-24,410

-6,809

-7,708

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

1,624

2,667

3,194

3,083

2,088

271

275

Common stock issued for services

-

-

29

23

-

-

-

Depreciation and amortization

22

28

48

94

51

15

7

Noncash interest

234

272

354

522

417

300

22

Amortization of debt discount

81

94

117

100

97

99

4

Amortization of premium/discount on short-term investments

52

100

9

-3

-8

-

-

Lease asset amortization and liability accretion, net

-6

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability

-

-

-

-

65

-37

34

Change in fair value of preferred stock purchase rights

-

-

-

-

-

-

84

Deferred rent

-

11

60

-53

-4

45

8

Deferred revenue

-

-3,000

1,741

-2,094

-

-

-

Deferred revenue

-

-

-

-

-3,550

6,903

-

Changes in assets and liabilities:
Prepaid expenses and other assets

-651

-92

356

42

424

1,701

-9

Accounts payable and accrued expenses

-3,421

4,142

776

-2,203

6,144

2,282

-

Accounts payable and accrued expenses

-

-

-

-

-

-

443

Accrued compensation and related expenses

-109

-30

-94

425

355

390

152

Net cash used in operating activities

-23,650

-30,783

-13,243

-27,150

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-19,163

1,758

-6,670

Purchase of property and equipment

-

-

39

3

127

70

7

Purchases of available-for-sale short-term investments

4,980

32,869

13,992

17,506

-

-

-

Purchases of available-for-sale short-term investments

-

-

-

-

12,790

-

-

Proceeds from the maturity of available-for-sale short-term investments

19,000

24,000

17,705

19,582

2,000

-

-

Net cash provided by investing activities

14,020

-8,869

3,674

2,073

-

-

-

Cash flows from financing activities
Net cash provided by investing activities

-

-

-

-

-10,917

-70

-7

Proceeds from long-term debt

-

7,000

8,000

-

10,000

7,500

2,500

Repayment of long-term debt

1,400

8,320

8,850

2,000

9,930

920

-

Proceeds from sale of common stock and warrants, net of offering costs

2,294

36,456

4,141

21,236

-

-

-

Proceeds from sale of common stock, net of offering costs paid in the current period

-

-

-

-

36,204

-1,250

-

Proceeds from sale of preferred stock, net of offering costs

-

-

-

-

-

25,654

3,994

Proceeds from issuance of common stock under equity plans

32

263

172

178

179

52

-

Payment of tax withholdings related to net share settlements of vested restricted stock awards

20

78

137

-

-

-

-

Net cash provided by (used in) financing activities

906

35,321

3,326

19,414

-

-

-

Decrease in cash and cash equivalents

-8,724

-4,331

-6,243

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

36,453

31,036

6,494

Increase in cash and cash equivalents

-

-

-

-5,663

6,373

32,724

-183

Supplemental disclosure of cash flow information
Interest paid

612

642

664

622

428

270

4

Supplemental schedule of noncash investing and financing activities
Issuance of preferred stock warrants in connection with long-term debt

-

-

-

-

-

186

63

Issuance of common stock warrants in connection with long-term debt

-

98

174

-

138

-

-

Issuance of common stock in connection with common stock purchase agreement

450

-

793

-

-

-

-